Health Management (NYSE:HMA) Outperforming Industry in Revenue Growth

Health Management (NYSE:HMA) is in the middle of a major turnaround, leading the sector in revenue growth. Soleil Securities has maintained their "Buy" rating on them while raising their price target.

Soleil reported, "HMA is in the heart of its turnaround phase, outperforming the industry on revenue growth (solid surgical growth) and same-hospital margin expansion (incremental cost control), and is aggressively building its revenue base via attractively priced acquisitions. We continue to recommend purchase of HMA shares."

Earnings estimates for full year 2011 were raised from $0.67 to $0.72, and EBITDA from $782 million to $800 million.

Health Management closed up Friday at $8.67, gaining $0.05, or 0.58 percent. Soleil has a price target of $10 on them, raising it from $9.